PATENT CLAIM ANALYSIS

Application Number: 15780732
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "049000"]

Abstract:
Provided relates to conjugates including cytarabine and an amino acid for use in the treatment of cancer. Further, the subject matter relates to conjugates of cytarabine and aspartic acid for use in the treatment of hematological cancers in medically compromised patients.

Claim (Index 42):
A method of treating a neoplastic disease comprising administering to a subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, having the general formula (I):\n A-Cytarabine \u2003\u2003(I) wherein A denotes an amino acid residue, the amino acid is selected from the group consisting of aspartic acid, glutamic acid, asparagine and glutamine; and wherein the subject is a medically compromised subject who is not amenable to treatment with cytarabine, the pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 94.0
- Lexical Diversity: 1.57143
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13762238', '12730097', '15277857', '15407122', '12267321']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6561411225219079
- 35 USC 102 Novelty (BERT): 0.5039261732186426
- Combined Prediction Score: 0.6409196275915814
- Mean Citation Score: 262.23539600000004
- Max Citation Score: 271.10385
- Similarity Product: 209.0396264356792

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test